platform is the key to the future. Very much hoping we obtain a deal with someone such as Omega or the UK government to licence or sell our test. Even if sales of initial nasal Covid test produce only a small revenue % it will be part of a much longer term strategy to get the readers and platform out there in the market place. The more readers they can push out the better as you have then built an ongoing revenue stream that will carry on much longer than Covid. Once the reader and platform are adopted then follow up with all the new tests anteo are capable of such as saliva Covid multiplex, sepsis etc and cash in. This is company making and would not surprise to see ADO in the asx top100 in the next year or two. well done team Anteo
ADO Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
